AETERNA ZENTARIS (NASDAQ:AEZS)
0.99
+0.01 (1.02%)
| AETERNA ZENTARIS (NASDAQ:AEZS) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $0.98 | 52 Week High | $3.25 | ||
| Open | $0.99 | 52 Week Low | $0.26 | ||
| Day High | $1.00 | P/E | N/A | ||
| Day Low | $0.97 | EPS | $0.00 | ||
| Volume | 44,805 | ||||
| More AEZS Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| AEZ | 14 | KERX | 11 |
| ACAS | 2 | JAZZ | 2 |
| AGCO | 2 | AIM | 2 |
| RODM | 2 | PGI | 2 |
| ATCO | 2 | CDII | 2 |
| DIET | 2 | GLW | 2 |
Entities who have mentioned AEZS
- StreetInsider.com Morning Movers | View Related Stories »
- Cowen & Co | View Related Stories »
- Deutsche Bank | View Related Stories »
- Unusual 11 Mid-Day Movers | View Related Stories »
- Highland Capital | View Related Stories »
- Northland Securities | View Related Stories »
- Notable Mergers and Acquisitions | View Related Stories »
- JMP Securities | View Related Stories »
- Barclays | View Related Stories »
- Canaccord Adams | View Related Stories »
- Robert W Baird | View Related Stories »
- SIPC | View Related Stories »
- Trading Radar | View Related Stories »
View All Major News StreetInsider.com Major News for AEZS
- Aeterna Zentaris (AEZS) Posts Q3 Loss of 19c, Beats by 2c
- AEterna (AEZS) Signs Development Deal With Sanofi-Aventis Worth $165M Or More
View All ReportsStreetInsider.com Reports on AEZS
- AEterna Zentaris (AEZS) Reports That Perifosine Partner Keryx Biopharma (KERX) Will Prersent Data from Phase 1/2 at 51st ASH Meeting
- Aeterna Zentaris (AEZS) Posts Q3 Loss of 19c, Beats by 2c
- Trading Radar for 11/11: Macy's (M), Progressive (PGR), Advanced Auto Parts (AAP), Computer Sciences (CSC) Report
- AEterna Zentaris (AEZS) Announces Publication of PI3K/Akt Article in Journal of Urology
- AEterna Zentaris (AEZS) Announces Positive AEZS-108 Efficacy Data from Phase 2
View All Press ReleasesCompany Press Releases on AEZS
- AEterna Zentaris Partner, Keryx Biopharmaceuticals, Announces Poster Presentation Highlighting Clinical Activity of Perifosine (KRX-0401) at 51st Annual Meeting of the American Society of Hematology
- Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
- AEterna Zentaris Reports Third Quarter 2009 Financial and Operating Results
- AEterna Zentaris: Scientific Article Supports Perifosine's Development in Kidney Cancer
- AEterna Zentaris to Announce Third Quarter 2009 Financial and Operating Results on November 11, 2009
StreetInsider Reports on AEZS by Category
View All BlogsBlogs on AEZS
- Analyst upgrades, downgrades and initiations: AXP, CHL, FLOW, GLW, GS ...
- My Take on Readers' Stock Picks
- Closing Update for Monday, August 17: Global Sell-Off Visits U.S.
- FDA Calendar Updates: Transcept Pharma Surges on Deal
- AEterna Zentaris: Expecting Good News?
Comments on AEZS
No comments are currently available.
